Clinical Trial: ECOG-ACRIN EA5182

ECOG-ACRIN EA5182

Status: Open

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Eligible for screening study DCP 001